Skip to content
FrontierPicks

Dormant

APPS · Digital Turbine, Inc.

Last analysed ·

Current thesis

Post-Q1 re-rating story: the 2026-08-05 print showed revenue $166.0M (+27% YoY), App Growth Platform +56%, adjusted EBITDA +69%, and FY2027 guidance raised to $650–670M — but the shares have given back most of the 43% pop and closed 2026-09-04 at $10.71, 25.6% under the $14.39 high with RSI 36. A maturing narrative with $343.5M of net long-term debt and no company-dated catalyst before roughly 2026-11-11.

Kill line

A weekly close below $9.50 (loses the shelf built after the 2026-08-05 earnings gap and returns price to pre-print territory); secondarily, any cut to the FY2027 $650–670M revenue guide raised on 2026-08-05, or the ~2026-11-11 Q2 print passing without App Growth Platform growth holding.

Pick status

Open commitment scored if the kill line above fires How this is scored →

Latest analysis and events for APPS —

As of 5 September 2026, the latest FrontierPicks analysis for Digital Turbine, Inc. (APPS): Post-Q1 re-rating story: the 2026-08-05 print showed revenue $166.0M (+27% YoY), App Growth Platform +56%, adjusted EBITDA +69%, and FY2027 guidance raised to $650–670M — but the shares have given back most of the 43% pop and closed 2026-09-04 at $10.71, 25.6% under the $14.39 high with RSI 36. A maturing narrative with $343.5M of net long-term debt and no company-dated catalyst before roughly 2026-11-11.

Kill line: A weekly close below $9.50 (loses the shelf built after the 2026-08-05 earnings gap and returns price to pre-print territory); secondarily, any cut to the FY2027 $650–670M revenue guide raised on 2026-08-05, or the ~2026-11-11 Q2 print passing without App Growth Platform growth holding.

Current Thesis

The leg on offer is a re-rating of a de-rated mobile ad-tech name whose growth engine has shifted from carrier-preload distribution to programmatic demand. On 2026-08-05 Digital Turbine reported fiscal Q1 2027 (quarter ended 2026-06-30) revenue of $166.0M, +27% YoY against $130.9M, and raised full-year FY2027 guidance to $650–670M in revenue and $145–155M in adjusted EBITDA, from $630–650M and $135–145M. Inside that print, App Growth Platform revenue was $56.6M, +56% YoY, while the older On Device Solutions line grew 15% to $110.0M. Adjusted EBITDA was $42.5M, +69% against $25.1M. Benzinga recorded the shares up 43% in the 2026-08-05 session.

What has happened since is the part that matters for the read. The 2026-09-04 close of $10.71 sits 25.6% below the $14.39 52-week high with RSI(14) at 36.0, and the three-month price change of +14.5% is a small fraction of the single-session August move — most of the post-print advance has been given back. No company-specific headline appears in the trailing 30-day news set after 2026-08-05; the only item dated 2026-09-03 is a generic market-movers roundup that does not name the company in its summary. So the narrative is maturing — the guidance raise is known, the sell-side reaction (Benchmark maintained Buy and lifted its target to $16 on 2026-08-05) is priced and stale, and the flow behind the 2026-08-05 gap has thinned across four weeks with no fresh bid arriving.

Bullish and bearish views on Digital Turbine, Inc.

The model's bull view on Digital Turbine, Inc. (APPS), in brief: App Growth Platform revenue of $56.6M grew 56% YoY in the quarter ended 2026-06-30, per the Q1 FY2027 release of 2026-08-05. The bear view: The balance sheet is the binding constraint. Both cases follow in full.

Bull Case

  • App Growth Platform revenue of $56.6M grew 56% YoY in the quarter ended 2026-06-30, per the Q1 FY2027 release of 2026-08-05. That is the segment carrying the mix shift; management attributed it to the brand demand side and DT Exchange on the supply side.
  • Adjusted EBITDA of $42.5M was +69% YoY against $25.1M, a faster rate than the 27% revenue growth — operating leverage showing up in the same quarter the mix shifted.
  • Guidance was raised, not reaffirmed: FY2027 revenue to $650–670M from $630–650M and adjusted EBITDA to $145–155M from $135–145M, both on 2026-08-05. FY2026 revenue was $565M. Management moved the bar in the first quarter of the year rather than waiting.
  • On Device Solutions, the legacy carrier-preload business that drove the 2021-era de-rating, grew 15% YoY to $110.0M — it is contributing rather than shrinking, which removes one of the standing bear objections to the story.
  • Benchmark maintained a Buy and raised its price target to $16 on 2026-08-05 (Benzinga). TipRanks shows a high forecast of $15.00 among the three analysts it tracks.

Bear Case

  • The balance sheet is the binding constraint. The 10-Q for the period ended 2026-06-30 shows long-term debt, net, of $343.5M against unrestricted cash of roughly $42.9M ($43.2M including restricted cash), with secured term-loan debt including exit and duration fees of $387.8M and an average interest rate of 11.65% during the quarter. Against a full-year adjusted EBITDA guide of $145–155M, debt service consumes a large share of the cash the operating story generates.
  • The same 10-Q flags an additional $5.0M duration fee if certain loans are not repaid by 2026-12-31 — a dated, contractual cost sitting one quarter out.
  • Reporting quality is an open question. The Q1 FY2027 results exhibit was amended (8-K/A, SEC accession 0001628280-26-053445) and carries a GAAP net loss of $11.3M, or $(0.09) per share; the version of the original release that circulated in the press carried $3.2M, or $(0.03). Revenue, adjusted EBITDA and the guidance range are identical across both, and the 10-Q summary carries $(0.09). A company that surged 43% on a release then amended it invites scrutiny of the next one.
  • Coverage is thin and the targets disagree with each other. MarketBeat shows a median target of $8.75 from two analysts, range $7.50–$10.00; TipRanks shows an average of $11.33 from three, range $7.50–$15.00. The 2026-09-04 close of $10.71 sits above one consensus and below the other. With two to three covering shops, one revision moves the published consensus materially.
  • Growth concentration: strip the App Growth Platform's 56% and the remaining $110.0M of On Device revenue compounded at 15%. The re-rating depends on the smaller, newer line sustaining its rate.

Setup & Price Structure

The 2026-09-04 close of $10.71 is 25.6% below the $14.39 52-week high. RSI(14) at 36.0 shows momentum with sellers and short of the sub-30 extreme where washouts typically register. The three-month price change of +14.5% against a 43% single-session move on 2026-08-05 puts the shares well inside the earnings gap rather than extended above it — this is not a name pressed against a rising moving average, it is one working back down through the range the August print created.

Crowding and positioning observables, stated as observables: a 43% one-day move on 2026-08-05 that put the name into multiple movers lists is the kind of participation spike that draws momentum flow; four weeks of no company-specific headlines since then, with price 25.6% off the high, is that flow leaving rather than compounding. Sell-side is thin (two to three shops in aggregator counts) and dispersed ($7.50 to $16.00 across published targets), so there is no broad institutional target cluster anchoring the price. No Form 4 activity appears in the filing set reviewed for this note; that is an absence of observation, not evidence of no insider activity. The next scheduled earnings date is roughly 2026-11-11 per aggregator calendars — nine weeks out, so the drift window is long and unpunctuated.

The structural question is whether the post-gap range holds. Above roughly $10, the market is still paying something for the raised FY2027 guide. A weekly close under $9.50 would say it has stopped.

Catalyst Calendar (next 30 days)

  • Through 2026-10-05: no company-dated event. There is no scheduled earnings release, no confirmed conference appearance and no regulatory date inside the 30-day window. This is the flat part of the calendar.
  • ~2026-11-11 (est.): Q2 FY2027 results, per aggregator earnings calendars (not confirmed by the company). First test of the $650–670M FY2027 revenue guide raised on 2026-08-05, and the first read on whether App Growth Platform growth holds near the 56% posted in Q1.
  • 2026-12-31: the date after which, per the 10-Q for the period ended 2026-06-30, an additional $5.0M duration fee attaches if certain loans are not repaid. Any refinancing or repayment announcement would land before the date, not on it.

What Would Change Our Mind

The structure breaks if the post-gap range fails and the market stops paying for the August guidance raise. Concretely: a weekly close below $9.50 removes the shelf built after the 2026-08-05 gap and returns the shares to pre-print territory, at which point the 27% revenue growth and the raised FY2027 range are no longer being capitalised by the tape.

On the fundamental side, three things would break the read independently of price. First, App Growth Platform growth decelerating sharply at the ~2026-11-11 print — the 56% rate is what the mix-shift argument rests on. Second, any FY2027 guidance cut from the $650–670M / $145–155M range set on 2026-08-05, which would make the August raise the high-water mark. Third, a further amendment, restatement or internal-control disclosure following the 8-K/A on the Q1 FY2027 exhibit, which would put the reported numbers themselves in dispute.

The passive failure mode is the calendar. With no dated company event before roughly 2026-11-11 and no theme cluster carrying the name, nine weeks of drift with no new bid would mature the story into one with a raised guide nobody is trading.

Correlation Notes

No current theme in the registry carries this name, so the setup is single-name and any group-move argument would be constructed rather than observed. The inferred (not measured) sensitivities: mobile ad-tech peers on the demand and exchange side, where a peer guidance cut on ad spend would read directly across to the $56.6M App Growth Platform line; Android and Google Play distribution policy, which governs the economics of the $110.0M On Device Solutions business; and small-cap risk appetite, given the market capitalisation and the thin analyst coverage.

The less obvious link is rates. With secured term-loan debt of $387.8M including fees at an 11.65% average rate during the quarter ended 2026-06-30 and $42.9M of unrestricted cash, refinancing terms are a direct input to equity value here in a way they are not for an unlevered peer. Moves in high-yield spreads matter to this name more than to the ad-tech complex it screens with.

Notes

  • Fiscal year ends 31 March: the "Q1 FY2027" figures cited throughout cover the quarter ended 2026-06-30.
  • The Q1 FY2027 earnings exhibit was amended via 8-K/A; GAAP net loss differs between the original ($3.2M) and amended ($11.3M) versions, while revenue and adjusted EBITDA do not.
  • Analyst coverage is thin — aggregators count two to three firms — so published consensus targets swing on a single revision and range from $7.50 to $16.00.
  • Secured term-loan debt carried an 11.65% average interest rate in the June-2026 quarter, with a $5.0M duration fee tied to a 2026-12-31 repayment condition.

Related · shared themes

APGE

Apogee Therapeutics, Inc.

The all-cash takeout settled: the AbbVie merger became effective 2026-09-03 at $135.11 per share (~$10.9B equity value), trading was halted after the 2026-09-02 close of $135.07 and Nasdaq suspended the stock 2026-09-04. The leg terminated at its cap with the $130 band never breached, Form 25 requested and Form 15 to follow, leaving a resolved situation with no tradeable catalyst under this symbol.

SUPREME

ATAI

AtaiBeckley Inc.

All named antitrust gates are retired: HSR expired 2026-08-28, the UK CMA had no further questions on 2026-08-21, Germany cleared 2026-07-30, and the ACCC's 14-day waiting period runs to 10:00 a.m. ET on 2026-09-10. Only the 2026-09-08 shareholder vote and the guided Q3 close remain. Above the $6.75 cash leg, the entire premium is an unpublished CVR worth up to $2.50 — a saturated situation under a contractual $9.25 ceiling.

SUPREME

HALO

Halozyme Therapeutics, Inc.

Royalty-compounding re-rating: the 2026-08-06 Q2 print beat at $481.0M vs $407.5M consensus and lifted the FY26 non-GAAP EPS guide to $8.65–9.00 from $7.75–8.25, and the stock closed 2026-09-04 at $110.19, 0.5% off its 52-week high. The 09-09/09-15/09-16 conference window is the only near-term new information before the ~November Q3 print.

HIGH

HZO

MarineMax, Inc.

Deal pin rather than a growth story: the $53.00 all-cash Safe Harbor/Blackstone Infrastructure take-private signed 2026-08-09 leaves $0.89 to terms at the 2026-09-02 close of $52.11. The gap widened from $0.80 on 2026-08-21 while no preliminary merger proxy reached EDGAR and no HSR clearance was announced, so clearance and vote timing are now the whole story.

HIGH

See also · stocks to watch